Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Mikkel ØstergaardRonald F Van VollenhovenAnna RudinMerete Lund HetlandMarte Schrumpf HeibergDan C NordströmMichael T NurmohamedBjorn GudbjornssonLykke Midtbøll ØrnbjergPernille BøyesenKristina LendKim Hørslev-PetersenTill UhligTuulikki SokkaGerdur GrondalSimon KrabbeJoakim LindqvistInger GjertssonDaniel GlinatsiMeliha Crnkic KapetanovicAnna-Birgitte AgaFrancesca FaustiniPinja ParmanneTove LorenzenCagnotto GiovanniJohan BackOliver HendricksDaisy VedderTuomas RannioEmma GrenholmMaud Kristine LjosåEli BrodinHanne LindegaardAnnika SöderberghMilad RizkAlf KastbomPer LarssonLine UhrenholtSøren Andreas JustDavid J StevensTrine Bay LaurbjergGunnstein BaklandInge Christoffer OlsenEspen A HaavardsholmJon Lampanull nullPublished in: Annals of the rheumatic diseases (2023)
NCT01491815.